XML 75 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Sanofi) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2011
Dec. 31, 2001
Alliances and Collaborations Statement [Line Items]            
Net sales $ 4,443 $ 5,434 $ 9,694 $ 10,445    
Profit distributions to Sanofi     (1,056) (1,319)    
Equity in net income of affiliates (53) (62) (110) (144)    
Other (income)/expense (18) (31) 5 (169)    
AVAPRO AVALIDE [Member]
           
Alliances and Collaborations Statement [Line Items]            
Net sales 117 251 324 541    
Sanofi [Member] | AVAPRO, AVALIDE, and PLAVIX [Member] | Supply Activities And Development And Opt Out Royalties [Member]
           
Alliances and Collaborations Statement [Line Items]            
Other (income)/expense (39) 1 (45) 15    
Sanofi [Member] | Territory Covering Americas and Australia [Member] | AVAPRO, AVALIDE, and PLAVIX [Member]
           
Alliances and Collaborations Statement [Line Items]            
Controlling interest ownership percentage 50.10%   50.10%      
Noncontrolling interest ownership percentage 49.90%   49.90%      
Net sales 778 2,045 2,595 4,023    
Royalty expense 141 397 508 755    
Noncontrolling interest - pre-tax 249 601 854 1,174    
Profit distributions to Sanofi (449) (702) (1,058) (1,301)    
Sanofi [Member] | Europe Comarketing Countries and Other [Member] | AVAPRO, AVALIDE, and PLAVIX [Member]
           
Alliances and Collaborations Statement [Line Items]            
Net sales 80 71 163 145    
Sanofi [Member] | Territory Covering Europe and Asia [Member] | AVAPRO, AVALIDE, and PLAVIX [Member]
           
Alliances and Collaborations Statement [Line Items]            
Controlling interest ownership percentage 50.10%   50.10%      
Equity method investment ownership percentage 49.90%   49.90%      
Equity in net income of affiliates (58) (65) (118) (151)    
Profit distributions to BMS 62 67 129 127    
Investment in affiliates 26   26   37  
Net sales 319 382 638 761    
Gross profit 132 172 270 340    
Net income 120 142 242 282    
Sanofi [Member] | United States [Member] | AVAPRO AVALIDE [Member] | License Fee [Member]
           
Alliances and Collaborations Statement [Line Items]            
Payment to the Company for an interest in a license           350
Amortization income - upfront, milestone and other licensing payments (8) (8) (16) (16)    
Deferred income $ 13   $ 13   $ 29